Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
about
New Developments in Chronic Myeloid Leukemia: Implications for TherapyManagement of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentAurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A ReviewRole of calcium-dependent protein kinases in chronic myeloid leukemia: combined effects of PKC and BCR-ABL signaling on cellular alterations during leukemia developmentThe growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABLResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsHIV-1 Protease Inhibitors from Inverse Design in the Substrate Envelope Exhibit Subnanomolar Binding to Drug-Resistant VariantsEqually Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase ConformationsAllelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemiaAbcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitroApplication of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemiaInterferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML PatientsBCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CMLMisfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.New dosing schedules of dasatinib for CML and adverse event managementDasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinibEfficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture.Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.The influence of Cox-2 and bioactive lipids on hematological cancers.Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity.Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutationExpression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps.Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemiaJacarelhyperol A induced apoptosis in leukaemia cancer cell through inhibition the activity of Bcl-2 proteins.Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.
P2860
Q26745669-7DB62E03-547A-4985-AB72-DFA7DCCE9D32Q26766299-22FF5F07-4FEE-4F09-99B6-FBEB1919BC83Q26783412-F733298C-F389-4C55-89B2-2F44EEEF66A3Q26861674-75A15ACA-60B2-4651-BD4A-EFCD6AD5DE28Q26866312-8E732CE0-EFD1-4C1B-B7BD-87CD964FB868Q27028181-181FDB48-9A8A-4CF4-BECF-44798643DDF3Q27650325-F2E9365C-8C12-4433-8E08-E0C825F8E34EQ27654059-72458EDB-69D9-4970-9826-0F4145F190A9Q27851396-AEA16FB8-A4A9-4418-930C-B1B5CF18CED6Q27851450-2A338365-8C98-400E-B6CF-8498C56ABE1EQ28477798-4B93E88D-9D56-4F6C-AECC-099941608D16Q28477903-4B52B4E7-4E49-438D-BC7E-EA73A23E2CA1Q28534259-3791AF76-5B2B-4B7E-8466-AF044262F7B1Q28552307-B2ADC06C-0F31-411F-B433-B8A15643764FQ30156840-A9C17137-B666-4409-A786-76FF94906F10Q30251920-F82142C3-E735-4FC8-BD82-514ACABA5801Q30357188-18698D29-4600-4DA8-AA1E-18F766EDBF8BQ30374671-46BA7326-4841-4008-8A21-AFE957A64410Q33285468-31DA22F8-2F00-4AF9-9805-27FD28396B22Q33357697-2283F37B-C0D6-419E-8125-1C133747FF0BQ33383407-4FECA0FF-6324-42F1-9136-6E17CA6442F6Q33384766-633D0399-751D-47CD-A893-06AD8583F52FQ33391185-D4C8E081-453D-4A3C-A1C9-7A8E3C2D60A1Q33414445-9AA3405A-015D-4621-A55A-776667CBB917Q33466143-E4955D8D-8A65-4E30-A1F3-2B08EB061168Q33513801-E96E1875-415F-4112-9666-8D9BEF10030EQ33566582-D50037CC-B8F7-4FD2-AFE3-C536AE17BAF5Q33602552-2A6768D5-AEFE-49F3-85A6-3AD08AA6051BQ33631185-0A2F8679-2332-4632-8796-2C5CA432AE9AQ33688673-FD689CB0-D10F-4667-9FF3-A632BD9AC033Q33766467-71DB5096-388E-4625-B090-0AEC5C88F886Q33902463-53885DD7-002A-4250-B792-F8B93D513014Q33967180-A217166D-8A13-4006-BDEF-95FCF35F8E47Q33988398-30A01A91-06E0-46F4-A9B3-129EF4550ECCQ34016866-567B1456-AF20-49E7-96F6-35C6EAD71A76Q34163458-37A2E904-11DB-474B-978C-2B2A52B22102Q34179630-561791B3-6D7E-46F7-A2CD-F743999DC099Q34251703-9ED7B435-EFC9-4EE3-ABAF-0D4AA74FD98AQ34256092-B6516DCD-EBD3-49D8-9BD4-5A8C7CA2B811Q34309928-DD8CF445-5E5E-4919-9C2C-FCC0307CCAAC
P2860
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
@en
type
label
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
@en
prefLabel
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
@en
P2093
P356
P1433
P1476
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
@en
P2093
Gschaidmeier H
Hanfstein B
Hehlmann R
La Rosée P
P2888
P304
P356
10.1038/SJ.LEU.2402741
P577
2002-11-01T00:00:00Z
P5875
P6179
1014157525